共 50 条
- [31] A phase II, multicenter, open-label, dose-finding study evaluating THIO sequenced with cemiplimab in patients with advanced NSCLCANNALS OF ONCOLOGY, 2022, 33 (07) : S1094 - S1094Ciuleanu, T-E.Joshi, R.Gryaznov, S.Vitoc, V.Obrocea, M.
- [32] Isatuximab plus atezolizumab in patients with advanced solid tumors: results from a phase I/II, open-label, multicenter studyESMO OPEN, 2022, 7 (05)Simonelli, M.Garralda, E.Eskens, F.Gil-Martin, M.Yen, C-JObermannova, R.Chao, Y.Lonardi, S.Melichar, B.Moreno, VYu, M-LBongiovanni, A.Calvo, E.Rottey, S.Machiels, J-PGonzalez-Martin, A.Paz-Ares, L.Chang, C-LMason, W.Lin, C-CReardon, D. A.Vieito, M.Santoro, A.Meng, R.Abbadessa, G.Menas, F.Lee, H.Liu, Q.Combeau, C.Ternes, N.Ziti-Ljajic, S.Massard, C.
- [33] Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study (vol 21, pg 671, 2020)LANCET ONCOLOGY, 2024, 25 (01): : E3 - E3Abou-Alfa, GkSahai, VHollebecque, A.
- [34] Efficacy and safety of tirabrutinib, highly selective Bruton's tyrosine kinase inhibitor, for oral treatment of pemphigus: a multicenter, open-label, uncontrolled, single-arm phase 2 studyJOURNAL OF INVESTIGATIVE DERMATOLOGY, 2021, 141 (10) : S155 - S155Yamagami, J.Ujiie, H.Aoyama, Y.Ishii, N.Tateishi, C.Ishiko, A.Ichijima, T.Hagihara, S.Hashimoto, K.Amagai, M.
- [35] A multicenter, open-label, phase II study of the immunogenicity and safety of a new prefilled syringe (liquid) formulation of Avonex in patients with multiple sclerosisCLINICAL THERAPEUTICS, 2004, 26 (04) : 511 - 521Phillips, JTRice, GFrohman, EGaer, LVScott, THaas, JEggenberger, EFreedman, MSStuart, WCunha, LJacobs, LOger, JArnold, DMurry, TJDiBiase, MJethwa, VGoelz, S
- [36] Safety and Efficacy of Orelabrutinib Monotherapy in Chinese Patients with Relapsed or Refractory Mantle Cell Lymphoma: A Multicenter, Open-Label, Phase II StudyBLOOD, 2019, 134Song, YuqinSong, YongpingLiu, LihongZhang, MingzhiLi, ZhimingJi, ChunyanXu, WeiLiu, TingXu, BingWang, XinGao, SujunZhang, HuilaiHu, YuLi, YanCheng, YingYang, HaiyanCao, JunningZhu, ZunminHu, JiandaZhang, WeiJing, HongmeiDing, KaiyangLu, ZhengguangZhang, BinZhao, RenbinXu, ZhixinZhu, Jun
- [37] A phase II, open-label, multicenter study of GW572016 in patients with trastuzumab-refractory metastatic breast cancer.JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 196S - 196SBlackwell, KLKaplan, EHFranco, SXMarcom, PKMaleski, JESorensen, MJBerger, MS
- [38] Camrelizumab plus famitinib in patients with metastatic colorectal cancer: Results from an open-label, multicenter phase II basket study.JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)Liu, TianshuYang, MudanLi, JinPan, YueyinYuan, YingYi, ShanyongWang, JunshengCheng, YingFeng, JifengGao, SheganWang, XichengQu, SongZhang, XizhiLu, JinXiu, PengWang, ShuniYang, XinfengFan, Jia
- [39] Atezolizumab plus Bevacizumab in Patients with Unresectable or Metastatic Mucosal Melanoma: A Multicenter, Open-Label, Single-Arm Phase II StudyCLINICAL CANCER RESEARCH, 2022, 28 (21) : 4642 - 4648Mao, LiliFang, MeiyuChen, YuWei, XiaotingCao, JunLin, JingZhang, PengChen, LingCao, XiaoChen, YujunGuo, JunSi, Lu
- [40] TORNADO: A randomized multicenter open-label phase II study evaluating retifanlimab in combination with neoadjuvant chemotherapy in patients with selected retroperitoneal sarcomasANNALS OF ONCOLOGY, 2022, 33 (07) : S1242 - S1243Albert, S.Italiano, A.Toulmonde, M.Cousin, S.Bahleda, R.Brahmi, M.Watson, S.Auzanneau, C.Douiri, N.Poignie, L.Lortal, B.Le Loarer, F.Bellera, C.